Enhancing Drug Compliance in Lipid-Lowering Treatment
Abstract
Hyperlipidemia and the atherosclerotic conditions that result from it are well recognized as major contributors to coronary heart disease (CHD). Fortunately, several large-scale clinical trials have shown that there are effective treatments that can substantially lower atherogenic lipid levels and thereby reduce the risk of CHD mortality and morbidity. However, duplication of these dramatic trial results can be negatively affected in "real life" clinical practice by an important issue: compliance. No medications will work if patients do not take them. Unfortunately, patients who need lipid-lowering therapy are likely to need it long-term, perhaps for a lifetime. Yet, many do not adhere to the prescribed medication regimen. This article reviews some major studies of compliance for lipid-lowering drugs. The reasons why patients do not take them as prescribed vary: poor education, lack of understanding, cost, provider indifference, and others. Achieving compliance requires a multifaceted approach. It can be enhanced by encouraging patients to talk openly about their medication habits and by convincing them of the long-term benefits of reaching and maintaining target low-density lipoprotein cholesterol levels. Although more studies focusing on compliance specifically regarding CHD are needed, the current literature does provide some guidance. Arch Fam Med. 2000;9:1169-1175
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The proportion of individuals compliant (≥80% adherence) with lipid-lowering or antihypertensive drugs typically ranges from 65% to 85% in clinical trials to <50% in clinical practice.
“The proportion of individuals compliant (Ն80% adherence) with lipid-lowering or antihypertensive drugs typically ranges from 65% to 85% in clinical trials to Ͻ50% in clinical practice.106 -108”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [107]
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · see citing works
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works
Persistence of Use of Lipid-Lowering Medications
Avorn, J., Monette, J., Lacour, A. S., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 635 · see citing works
Andrade, S. E., Walker, A. M., Gottlieb, L. K., Hollenberg, N., Testa, M. A., Saperia, G., & Platt, R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321703 · Cited by 391 · see citing works
Premature mortality from coronary heart disease. The Framingham study
Gordon, T. (1971) · JAMA · doi:10.1001/jama.215.10.1617 · Cited by 389 · see citing works
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315 · see citing works
Compliance with cardiovascular disease prevention strategies: A review of the research
Burke, L. E., Dunbar-Jacob, J. M., & Hill, M. N. (1997) · Annals of Behavioral Medicine · doi:10.1007/bf02892289 · Cited by 286 · see citing works
Nieto, F. J. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.7.677 · Cited by 169 · see citing works
Hoerger, T. J., BALA, M. M., Bray, J. W., Wilcosky, T. C., & LaRosa, J. C. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00227-6 · Cited by 167 · see citing works
Self-citationRand, C. S. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90014-4 · Cited by 154 · see citing works
Contribution of the framingham study to preventive cardiology
Kannel, W. B. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90203-2 · Cited by 149 · see citing works
The problem of compliance to cholesterol altering therapy
Insull, W. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.112133000.x · Cited by 123 · see citing works
Factors affecting patient compliance with antihyperlipidemic medications in an HMO population.
Sung, J. C., Nichol, M. B., Venturini, F., Bailey, K. L., McCombs, J. S., & Cody, M. (1998) · PubMed · Cited by 111 · see citing works
The West of Scotland Coronary Prevention Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015165 · Cited by 80 · see citing works
Chockalingam, A., Bacher, M., Campbell, N. R. C., et al. (1998) · Canadian Journal of Public Health · doi:10.1007/bf03404491 · Cited by 34 · see citing works
Strandberg, T. E., Lehto, S., Pyörälà, K., et al. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015166 · Cited by 21 · see citing works
Patient adherence: a 'risk factor' for cardiovascular disease.
Luepker, R. V. (1994) · PubMed · Cited by 18 · see citing works
Management of hyperlipidaemia after coronary revascularisation: follow up study
Delacrétaz, E., Michalopoulos, P., Ruiz, J., et al. (1998) · BMJ · doi:10.1136/bmj.316.7143.1499 · Cited by 14 · see citing works
The Importance of lowering cholesterol in patients with coronary heart disease
Eisenberg, D. (1998) · Clinical Cardiology · doi:10.1002/clc.4960210204 · Cited by 13 · see citing works
Tomorrow's world: atherosclerosis in the year 2000
SHEPHERD, J. (1997) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00011-9 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease
Mozaffarian, D., Wilson, P. W. F., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.738732 · Cited by 456 · see citing works
Parris, E. S., Lawrence, D. B., Mohn, L. A., & Long, L. B. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.595 · Cited by 155 · see citing works
Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy
Benner, J. S., Tierce, J. C., Ballantyne, C. M., Prasad, C., Bullano, M. F., Willey, V. J., Erbey, J., & Sugano, D. S. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422003-00003 · Cited by 115 · see citing works
Assessment of Adherence Measures with Different Stimulants Among Children and Adolescents
Sanchez, R. J., Crismon, M. L., Barner, J. C., Bettinger, T., & Wilson, J. P. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.7.909 · Cited by 101 · see citing works
- Authors
- LaRosa, J. H.
- Venue
- Archives of Family Medicine
- Publisher
- CLOCKSS Archive
- Published
- 2000-11-01
- Volume
- 9
- Issue
- 10
- Pages
- 1169-1175
- ISSN
- 1063-3987 (ISSN-L)
- OpenAlex
- W2043343801
- Cited by
- 77
- References
- 22
- Citations by year
- 2023: 1 · 2022: 1 · 2019: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 4
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Family Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacy and Medical Practices
- Keywords
- medication adherence, lipid-lowering therapy, hyperlipidemia, coronary artery disease, patient adherence, LDL cholesterol targets, patient education, drug costs, chronic drug administration, atherosclerosis
- MeSH terms
- Communication, Humans, Hyperlipidemias, Patient Compliance, Patient Education as Topic, Physician-Patient Relations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
